OraLiva

Website

OraLiva, Inc.

1 Investors
Medical Technology
DURHAM, NC

OraLiva, Inc. is an innovative medical technology company specializing in the development of advanced early detection diagnostics for oral cancer. By leveraging cutting-edge technology, the company aims to address the critical issue of late-stage cancer diagnosis, enhancing patient outcomes through timely intervention.

Products & Team

ONC-InCyt Technology

Diagnostic TechnologySeed

The ONC-InCyt technology is a portable, programmable cytology platform designed for point-of-care use. This advanced diagnostic tool utilizes a microfluidic engine to process cells and deliver reliable diagnostics for oral cancer and oral dysplasia.

Value Proposition

The ONC-InCyt technology addresses the pervasive issue of late-stage cancer diagnosis, enabling healthcare providers to identify oral cancers and dysplasia at the earliest possible stage, thus improving patient outcomes through prompt treatment.

Pain Points

Patients and providers face challenges with late-stage cancer diagnoses, which result in poor prognoses. OraLiva addresses this pain point by providing a tool that ensures early detection and potentially life-saving interventions.

Noninvasive and painless procedureHigh sensitivity and specificity in cancer detectionAI-linked diagnostic capabilitiesRapid results obtainable at the point of careVisual representation of early cancer signs via 'cyto-signatures'Clinically validated through extensive studies
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
DURHAM, NC
Primary headquarters

Funding History

Total Raised:
$1.5M
E

Option to Acquire, Security Offering

February 2025
$2.3M
Target
Use of Proceeds
Proceeds will be used for working capital, which may include normal compensation to executive officers.
Progress
67%
Raised
$1.5M
Target
$2.3M
#000196356925000002